These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25618600)

  • 21. Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy.
    Steensma MR; Tyler WK; Shaber AG; Goldring SR; Ross FP; Williams BO; Healey JH; Purdue PE
    PLoS One; 2013; 8(7):e69101. PubMed ID: 23922683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
    Hiruma Y; Hirai T; Tsuda E
    Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone.
    Lou Z; Yang Y; Ren T; Tang S; Peng X; Lu Q; Sun Y; Guo W
    Med Oncol; 2013; 30(3):606. PubMed ID: 23690270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
    Wang T; Yin H; Wang J; Li Z; Wei H; Liu Z; Wu Z; Yan W; Liu T; Song D; Yang X; Huang Q; Zhou W; Xiao J
    Oncotarget; 2015 Aug; 6(22):18980-96. PubMed ID: 26053181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.
    Sato K; Lee JW; Sakamoto K; Iimura T; Kayamori K; Yasuda H; Shindoh M; Ito M; Omura K; Yamaguchi A
    Am J Pathol; 2013 May; 182(5):1890-9. PubMed ID: 23499553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of RANK/RANKL and OPG in multiple myeloma].
    Zdzisińska B; Kandefer-Szerszeń M
    Postepy Hig Med Dosw (Online); 2006; 60():471-82. PubMed ID: 17013366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor.
    Hu Y; Yu S
    Zhonghua Bing Li Xue Za Zhi; 2002 Apr; 31(2):128-31. PubMed ID: 12419159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cytokines in bone diseases. Genetic disorders of RANKL-RANK-OPG system].
    Tokuyama N; Tanaka S
    Clin Calcium; 2010 Oct; 20(10):1532-8. PubMed ID: 20890036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
    Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
    Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
    Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
    Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
    Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
    Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis.
    Ainola M; Mandelin J; Liljeström M; Konttinen YT; Salo J
    Clin Exp Rheumatol; 2008; 26(2):240-6. PubMed ID: 18565244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Osteoporosis and RANKL signal].
    Nakamura M; Udagawa N
    Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.